The global monoclonal antibody therapy market is poised for remarkable growth, with projections indicating a substantial increase from USD 205 billion in 2022 to a staggering USD 479.2 billion by 2030. This growth trajectory represents an impressive compound annual growth rate (CAGR) of 11.2% over the forecast period spanning from 2023 to 2030.

Get Sample  PDf @ https://www.snsinsider.com/sample-request/3393 

Key Players

The major key players are Novartis AG, Pfizer, GlaxoSmithKline, Amgen, Merck & CO, Daiichi Sankyo Company, Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Johnson & Johnson and others.

Monoclonal antibody therapy has revolutionized the treatment landscape across various therapeutic areas, offering targeted and personalized treatment options for a wide range of diseases, including cancer, autoimmune disorders, infectious diseases, and chronic inflammatory conditions. The increasing prevalence of these diseases, coupled with the growing acceptance of monoclonal antibody therapies among healthcare professionals and patients, is driving the market's expansion.

Key factors fueling the growth of the monoclonal antibody therapy market include advancements in biotechnology, enabling the development of novel monoclonal antibodies with enhanced efficacy and reduced side effects. Additionally, the rising demand for biologics as a preferred treatment option over traditional therapies, coupled with favorable regulatory frameworks facilitating the approval and commercialization of monoclonal antibody drugs, further contributes to market growth.

The COVID-19 pandemic has underscored the importance of monoclonal antibody therapies in combating infectious diseases, with several monoclonal antibodies receiving emergency use authorization for the treatment of COVID-19 patients. This unprecedented global health crisis has accelerated research and development efforts in monoclonal antibody technology, fostering innovation and driving market growth.

North America currently dominates the global monoclonal antibody therapy market, attributed to the presence of leading pharmaceutical companies, robust healthcare infrastructure, and high healthcare expenditure. However, Asia-Pacific is poised to witness significant growth during the forecast period, driven by increasing healthcare investments, rising prevalence of chronic diseases, and expanding access to advanced healthcare services.

Market Segmentation

Source Type

  • Murine

  • Chimeric

  • Humanized

  • Human

Application Type

  • Oncology

  • Autoimmune Diseases

  • Infectious Diseases

  • Others

Production Type

  • In Vivo

  • In Vitro

End-Use Outlook

  • Hospitals

  • Speciality Centers

  • Others

 

These companies are actively engaged in strategic initiatives such as research and development collaborations, product launches, and mergers and acquisitions to strengthen their market presence and capitalize on emerging opportunities.

As the demand for targeted and personalized therapies continues to surge, stakeholders in the healthcare sector are urged to prioritize investments in monoclonal antibody research and development to address unmet medical needs and improve patient outcomes.

 

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Akash Anand – Head of Business Development & Strategy

info@snsinsider.com

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

Website: https://www.snsinsider.com